Glenmark Specialty S.A., a subsidiary of India-based Glenmark Pharmaceuticals, has entered into a licensing agreement with China’s Jiangsu Hansoh Pharmaceutical Group Co. for the oncology drug Aumolertinib. The agreement grants Glenmark exclusive rights to develop and commercialize Aumolertinib in several high-potential markets, including the Middle East, Africa, Southeast and South Asia, Australia, New Zealand, Russia, and the Caribbean. In return, Hansoh Pharma will receive an upfront payment of tens of millions of dollars, followed by potential milestone payments of over $1 billion, as well as tiered royalties on net sales.<\/p>\n
Aumolertinib is a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) used to treat non-small cell lung cancer (NSCLC). The drug has already received marketing authorization in the UK and China, and has been approved for four indications in China. It is also marketed in the UK and Europe under the brand names Ameile and Aumseqa. The partnership strengthens Glenmark’s oncology strategy across these regions, providing access to a promising new treatment for patients with NSCLC.<\/p>\n
The agreement marks a significant milestone for Hansoh Pharma, as Aumolertinib is the company’s first innovative drug to be approved in an overseas market. It is also the first China-developed EGFR-TKI to be launched internationally. The deal demonstrates the growing importance of partnerships between pharmaceutical companies to bring new treatments to market and expand their global reach. With the potential for milestone payments of over $1 billion, the agreement also highlights the significant value of innovative oncology treatments and the growing demand for effective therapies in this field. Overall, the partnership between Glenmark and Hansoh Pharma has the potential to bring a new and effective treatment option to patients with NSCLC in several regions, and marks an important step forward in the development of innovative oncology therapies.<\/p>\n","protected":false},"excerpt":{"rendered":"
Glenmark Specialty S.A., a subsidiary of India-based Glenmark Pharmaceuticals, has entered into a licensing agreement with China’s Jiangsu Hansoh Pharmaceutical Group Co. for the oncology drug Aumolertinib. The agreement grants Glenmark exclusive rights to develop and commercialize Aumolertinib in several high-potential markets, including the Middle East, Africa, Southeast and South Asia, Australia, New Zealand, Russia, […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[23,2],"tags":[],"class_list":["post-89682","post","type-post","status-publish","format-standard","hentry","category-glenmark","category-pharma"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89898,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/02\/03\/glenmark-pharmaceuticals-sets-sights-on-fy28-for-debut-of-oncology-drugs-and-expansion-of-profit-margins-reports-etpharma\/","url_meta":{"origin":89682,"position":0},"title":"Glenmark Pharmaceuticals sets sights on FY28 for debut of oncology drugs and expansion of profit margins, reports ETPharma.","author":"Team Small News","date":"February 3, 2026","format":false,"excerpt":"Glenmark Pharmaceuticals, a leading Indian pharmaceutical company, has expressed confidence that its cancer drug, Trastuzumab Rezetecan (SHR-A1811), will enter licensed markets by FY28, driving an improvement in both gross and EBITDA margins. The company has guided for an EBITDA margin of 23% for the ongoing fiscal year and expects its\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89712,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/27\/glenmark-pharmaceuticals-usa-has-introduced-a-multiple-dose-vial-of-epinephrine-injection\/","url_meta":{"origin":89682,"position":1},"title":"Glenmark Pharmaceuticals USA has introduced a multiple-dose vial of epinephrine injection.","author":"Team Small News","date":"December 27, 2025","format":false,"excerpt":"Glenmark Pharmaceuticals Inc, USA, has launched Epinephrine Injection USP, a bioequivalent and therapeutically equivalent product to the reference listed drug manufactured by BPI Labs, LLC. The product is available in a 30 mg\/30 mL (1 mg\/mL) Multiple-Dose Vial and is intended for the U.S. market. According to IQVIA sales data,\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89851,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/25\/glenmark-pharmaceuticals-names-neha-jangale-as-new-head-of-learning-and-development\/","url_meta":{"origin":89682,"position":2},"title":"Glenmark Pharmaceuticals Names Neha Jangale as New Head of Learning and Development","author":"Team Small News","date":"January 25, 2026","format":false,"excerpt":"Glenmark Pharmaceuticals, a leading global pharmaceutical company, has announced the appointment of Neha Jangale as the Head of Learning and Development (L&D). This strategic move aims to further strengthen the company's commitment to employee development and growth. Neha Jangale, with her extensive experience in the field of human resources, will\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89863,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/26\/glenmark-introduces-emergency-epinephrine-injection-drug-store-news\/","url_meta":{"origin":89682,"position":3},"title":"Glenmark introduces emergency epinephrine injection – Drug Store News","author":"Team Small News","date":"January 26, 2026","format":false,"excerpt":"Glenmark Pharmaceuticals has launched an epinephrine injection, which is the first FDA-approved generic version of Auvi-Q, according to a report by Drug Store News. The epinephrine injection, also known as epinephrine injection, USP, is a prescription medication used to treat life-threatening allergic reactions, including anaphylaxis. The medication is available in\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89748,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/04\/delhi-high-court-bars-dr-reddys-from-producing-venusia-sunscreens-bearing-the-sun-logo\/","url_meta":{"origin":89682,"position":4},"title":"Delhi High Court bars Dr Reddy’s from producing VENUSIA sunscreens bearing the SUN logo.","author":"Team Small News","date":"January 4, 2026","format":false,"excerpt":"The Delhi High Court has issued an interim order restraining Dr. Reddy's Laboratories from manufacturing and selling its VENUSIA sunscreens with a label that includes the word \"SUN\". The court's decision comes in response to a lawsuit filed by Glenmark Pharmaceuticals, which claims that Dr. Reddy's is infringing on its\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89821,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/19\/sun-pharma-sets-sights-on-10-billion-organon-takeover-to-bolster-us-presence\/","url_meta":{"origin":89682,"position":5},"title":"Sun Pharma Sets Sights on $10 Billion Organon Takeover to Bolster US Presence","author":"Team Small News","date":"January 19, 2026","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd., India's largest drug manufacturer, is considering a monumental acquisition of Organon, a US-based company specializing in women's health and biosimilars. The potential deal, valued at $10 billion, is being led by the company's founder, Dilip Shanghvi. If successful, this acquisition would be a significant milestone for\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89682"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89682\/revisions"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}